Latigo Biotherapeutics, Inc. (LTGO)
Nasdaq · Healthcare · Biotechnology
$16.63+4.59%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- 52-week range
- $15.67 – $25.93
- 52-week change
- −12.88%
- EPS (trailing)
- −$2.52
- Next earnings
- Nov 12, 2026
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Headquarters: Thousand Oaks, United States · 66 employees · latigobio.com